Safety of enzyme replacement therapy for mucopolysaccharidosis II

被引：0
|
作者：
Almeida, Paulo H. R. F. [1 ,2 ]
de Lemos, Livia L. P. [1 ,2 ]
Alvares, Juliana [1 ,2 ]
Godman, Brian [3 ,4 ,5 ]
Bennie, Marion [3 ]
Acurcio, Francisco De A. [1 ,2 ]
Guerra Junior, Augusto A. [1 ,2 ]
机构：
[1] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil
[2] SUS Collaborating Ctr Technol Assessment & Excell, Belo Horizonte, MG, Brazil
[3] Univ Strathclyde, Glasgow, Lanark, Scotland
[4] Karolinska Inst, Stockholm, Sweden
[5] Univ Liverpool, Management Sch, Liverpool, Merseyside, England
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2018年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
479
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [21] Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England
    Broomfield, A.
    Davison, J.
    Roberts, J.
    Stewart, C.
    Hensman, P.
    Beesley, C.
    Tylee, K.
    Rust, S.
    Schwahn, B.
    Jameson, E.
    Vijay, S.
    Santra, S.
    Sreekantam, S.
    Ramaswami, U.
    Chakrapani, A.
    Raiman, J.
    Cleary, M. A.
    Jones, S. A.
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : 98 - 105
  • [22] Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
    Seo, Joo-Hyun
    Kosuga, Motomichi
    Hamazaki, Takashi
    Shintaku, Haruo
    Okuyama, Torayuki
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 21 : 67 - 75
  • [23] Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report
    Muenzer, J
    Lamsa, JC
    Garcia, A
    Dacosta, J
    Garcia, J
    Treco, DA
    ACTA PAEDIATRICA, 2002, 91 : 98 - 99
  • [24] The one year experience of enzyme replacement therapy for mucopolysaccharidosis II (Hunter syndrome).
    Muenzer, J
    Calikoglu, M
    Towle, D
    McCandless, S
    Kimura, A
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 623 - 623
  • [25] Enzyme replacement therapy in mucopolysaccharidosis type I
    Miebach, E
    ACTA PAEDIATRICA, 2005, 94 : 58 - 60
  • [26] Enzyme replacement therapy in feline mucopolysaccharidosis I
    Kakkis, ED
    Schuchman, E
    He, X
    Wan, Q
    Kania, S
    Wiemelt, S
    Hasson, CW
    O'Malley, T
    Weil, MA
    Aguirre, GA
    Brown, DE
    Haskins, ME
    MOLECULAR GENETICS AND METABOLISM, 2001, 72 (03) : 199 - 208
  • [27] Enzyme replacement therapy for mucopolysaccharidosis type IIID
    Chou, Tsui-Fen
    Moen, Derek
    Sauni, Chelsee
    Kan, Shih-hsin
    Wang, Feng
    Zhang, Xiaoyi
    Le, Steven
    Wood, Jill
    Ekins, Sean
    Dickson, Patricia I.
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S39 - S39
  • [28] Clinical benefit of enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome)
    Muenzer, J.
    Wraith, E.
    Beck, M.
    Giugliani, R.
    Harmatz, P.
    Eng, C. M.
    Vellodi, A.
    Martin, R.
    Ramaswami, U.
    Calikoglu, M.
    Vijayaraghavan, S.
    Puga, A.
    Ulbrich, B.
    Shinawi, M.
    Cleary, M.
    Wendt, S.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 28 - 28
  • [29] Clinical benefit of enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome)
    Eng, Christine
    Muenzer, J.
    Wraith, E.
    Beck, M.
    Giugliani, R.
    Harmatz, P.
    Vellodi, A.
    Martin, R.
    Ramaswami, U.
    Calikoglu, M.
    Vijayaraghavan, S.
    Puga, A.
    Ulbrich, B.
    Shinawi, M.
    Cleary, M.
    Wendt, S.
    MOLECULAR GENETICS AND METABOLISM, 2007, 92 (04) : S18 - S18
  • [30] A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)
    Muenzer, Joseph
    Gucsavas-Calikoglu, Muge
    McCandless, Shawn E.
    Schuetz, Thomas J.
    Kimura, Alan
    MOLECULAR GENETICS AND METABOLISM, 2007, 90 (03) : 329 - 337
12345